SCHEMBL5573564

SCHEMBL5573564

COc1cc([N+](=O)[O-])c(C=NNC(N)=NO)c(Cl)c1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
MAPT P10636 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
LMNA P02545 3/20 0.39
ALDH1A1 P00352 3/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KDM4E B2RXH2 1/20 0.39
CTSD P07339 3/20 0.39
F2 P00734 1/20 0.38
PRSS1 P07477 1/20 0.38
PRSS2 P07478 1/20 0.38
PRSS3 P35030 1/20 0.38
GRIN2D O15399 1/20 0.38
GRIN3B O60391 1/20 0.38
GRIN1 Q05586 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7747059 0.88 POLB (0.46) POLBTDP1MAPTSMN1; SMN2MEN1
SCHEMBL7747061 0.88 POLB (0.46) POLBTDP1MAPTSMN1; SMN2MEN1
SCHEMBL5574498 0.86 POLB (0.46) POLBTDP1MAPTSMN1; SMN2MEN1
SCHEMBL5573553 0.83 RPS6KA3 (0.43) POLBTDP1MAPTSMN1; SMN2MEN1
SCHEMBL5573558 0.83 RPS6KA3 (0.43) POLBTDP1MAPTSMN1; SMN2MEN1
SCHEMBL915475 0.82 MAPT (0.42) POLBTDP1MAPTSMN1; SMN2MEN1
SCHEMBL14806595 0.81 POLB (0.45) POLBTDP1MAPTSMN1; SMN2MEN1
SCHEMBL13673542 0.77 POLB (0.46) POLBTDP1MAPTSMN1; SMN2MEN1
SCHEMBL5570020 0.76 MAPT (0.50) POLBTDP1MAPTSMN1; SMN2MEN1
Hydrochloric Acid SCHEMBL915506 0.76 MAPT (0.49) POLBTDP1MAPTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070231267-A1 Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands ACURE PHARMA AB (SE) 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070231267-A1 Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands MC1R, MC5R, MCHR1 POLB 3668/4885TDP1 3518/4885MAPT 4502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.